Large-Cap Pharma Stocks Approach Record Highs Amid Tech Selloff
nashnova research
As AI-linked stocks sell off, Eli Lilly, AbbVie and other large-cap pharma names are pushing toward or setting all-time highs — the Health Care Select Sector SPDR ETF (XLV) gained 6.4% over five sessions. This means → capital is systematically rotating out of tech and into defensive assets with proven earnings.
Why is money moving from tech into pharma?
Markets are questioning whether AI capital spending can be sustained. News of slowing revenue growth at Anthropic accelerated the sell-off in tech.
This means → investors are asking: how long before the money poured into AI turns into profit? Once that confidence cracks, capital migrates to sectors already delivering earnings.
Large pharma — stable profits, strong cash flow — became the most direct recipient. XLV, heavily weighted toward Eli Lilly and AbbVie, rose 6.4% in five trading days.
What is pushing Eli Lilly toward its second-highest close ever?
Lilly's stock rose roughly 5% Thursday afternoon, on track for its second-highest closing price in history. The core pillar: dominance in the GLP-1 market — a class of gut-hormone drugs that lower blood sugar and suppress appetite.
In plain terms = GLP-1 is the hottest obesity / diabetes franchise in pharma right now, and Lilly leads it.
On top of that, two new weight-loss drugs are nearing FDA review. CEO Dave Ricks recently disclosed the company has completed 40 deals this year totaling $20 billion — an aggressive M&A push alongside organic growth.
What is the catalyst behind AbbVie's all-time high?
AbbVie closed at a record $283.48 on Wednesday and looked set to break it again Thursday.
The catalyst: new clinical data for its blockbuster drug Skyrizi (risankizumab). A subcutaneous formulation — letting patients inject at home instead of receiving IV infusions at a clinic — confirmed efficacy in Crohn's disease patients after 24 continuous weeks.
This means → the new formulation has a clear path to FDA approval, which would extend patent protection. Skyrizi generated $17.6 billion in sales last year; a patent extension directly safeguards that revenue stream.
How are other large pharma names performing?
Over the past five sessions: Gilead Sciences rose 8.9%, Amgen gained 8.6% — neither company issued any news this month. The moves are pure rotation.
Merck added 5.2%; UnitedHealth Group surged 10.1% this week on solid third-quarter results.
This reflects a sector-wide premium on earnings certainty — not a story confined to Lilly and AbbVie alone.
Why aren't small biotechs joining the rally?
The SPDR S&P Biotech ETF (XBI) fell 2.7% over the past month, diverging sharply from large-cap pharma.
In plain terms = most small biotechs are still burning cash on R&D with no stable profits. They are acutely sensitive to interest rates and funding conditions — if rates stay high, cheap capital stays out of reach.
This signals that the market is only willing to pay up for earnings already in the bank. Whether that preference holds depends on how deep the tech sell-off runs and where interest rates go next.
市场有风险，内容仅供研究参考，不构成投资建议。